JP2018511609A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018511609A5 JP2018511609A5 JP2017551276A JP2017551276A JP2018511609A5 JP 2018511609 A5 JP2018511609 A5 JP 2018511609A5 JP 2017551276 A JP2017551276 A JP 2017551276A JP 2017551276 A JP2017551276 A JP 2017551276A JP 2018511609 A5 JP2018511609 A5 JP 2018511609A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- binding fragment
- antigen
- administration
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims description 49
- 102000036639 antigens Human genes 0.000 claims description 49
- 108091007433 antigens Proteins 0.000 claims description 49
- 239000012634 fragment Substances 0.000 claims description 49
- 238000000034 method Methods 0.000 claims description 42
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims description 22
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims description 22
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims description 22
- 238000012423 maintenance Methods 0.000 claims description 20
- 102000003855 L-lactate dehydrogenase Human genes 0.000 claims description 10
- 108700023483 L-lactate dehydrogenases Proteins 0.000 claims description 10
- 230000003442 weekly effect Effects 0.000 claims description 10
- 206010018910 Haemolysis Diseases 0.000 claims description 7
- 206010022822 Intravascular haemolysis Diseases 0.000 claims description 7
- 150000001413 amino acids Chemical group 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 3
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims description 3
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 3
- 229960001230 asparagine Drugs 0.000 claims description 3
- 235000009582 asparagine Nutrition 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 229930182817 methionine Natural products 0.000 claims description 3
- 108010068617 neonatal Fc receptor Proteins 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 208000007536 Thrombosis Diseases 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 16
- 208000024891 symptom Diseases 0.000 description 6
- 230000009266 disease activity Effects 0.000 description 3
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562140711P | 2015-03-31 | 2015-03-31 | |
| US62/140,711 | 2015-03-31 | ||
| PCT/US2016/024624 WO2016160756A2 (en) | 2015-03-31 | 2016-03-29 | Identifying and treating subpopulations of paroxysmal nocturnal hemoglobinuria (pnh) patents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018511609A JP2018511609A (ja) | 2018-04-26 |
| JP2018511609A5 true JP2018511609A5 (cg-RX-API-DMAC7.html) | 2019-05-09 |
| JP6944375B2 JP6944375B2 (ja) | 2021-10-06 |
Family
ID=55702135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017551276A Active JP6944375B2 (ja) | 2015-03-31 | 2016-03-29 | 発作性夜間血色素尿症（ｐｎｈ）患者の亜集団の同定および処置 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20190135903A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3277715A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6944375B2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016160756A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2647846C (en) | 2006-03-31 | 2016-06-21 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| PL2202245T3 (pl) | 2007-09-26 | 2017-02-28 | Chugai Seiyaku Kabushiki Kaisha | Sposób modyfikowania punktu izoelektrycznego przeciwciała poprzez podstawienie aminokwasu w cdr |
| KR102269708B1 (ko) | 2008-04-11 | 2021-06-25 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| EP4231014A3 (en) | 2010-11-30 | 2024-08-14 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
| NZ711451A (en) | 2014-03-07 | 2016-05-27 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| IL278014B2 (en) | 2014-12-19 | 2023-10-01 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use |
| JP6174782B2 (ja) | 2014-12-19 | 2017-08-02 | 中外製薬株式会社 | 抗ｃ５抗体および使用方法 |
| RU2018141451A (ru) | 2016-05-27 | 2020-06-29 | Алексион Фармасьютикалс, Инк. | Способы лечения рефрактерной генерализованной миастении |
| MY191668A (en) | 2016-06-14 | 2022-07-06 | Regeneron Pharma | Anti-c5 antibodies and uses thereof |
| TWI831965B (zh) | 2016-08-05 | 2024-02-11 | 日商中外製藥股份有限公司 | Il-8相關疾病之治療用或預防用組成物 |
| AU2018230657A1 (en) * | 2017-03-06 | 2019-09-26 | The Trustees Of The University Of Pennsylvania | Anti-C5 antibodies and uses thereof |
| ES2965486T3 (es) * | 2017-07-27 | 2024-04-15 | Alexion Pharma Inc | Formulaciones de anticuerpos anti-C5 de alta concentración |
| MX2020004284A (es) | 2017-10-26 | 2020-10-28 | Alexion Pharma Inc | Dosis y administracion de anticuerpos anti-c5 para el tratamiento de la hemoglobinuria paroxistica nocturna (hpn) y el sindrome hemolitico uremico atipico (shua). |
| IL275264B1 (en) | 2017-12-13 | 2025-10-01 | Regeneron Pharma | Anti-C5 antibody combinations and their uses |
| US12404320B2 (en) | 2018-05-31 | 2025-09-02 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) in pediatric patients |
| US12460012B2 (en) | 2018-06-04 | 2025-11-04 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-C5 antibodies for treatment of atypical hemolytic uremic syndrome (aHUS) in pediatric patients |
| WO2020006266A1 (en) | 2018-06-28 | 2020-01-02 | Alexion Pharmaceuticals, Inc. | Methods of producing anti-c5 antibodies |
| US12098190B2 (en) | 2018-09-06 | 2024-09-24 | The Trustees Of The University Of Pennsylvania And | Humanized anti-C5 antibodies and uses thereof |
| KR20210084533A (ko) | 2018-10-30 | 2021-07-07 | 알렉시온 파마슈티칼스, 인코포레이티드 | 발작성 야간 혈색소뇨증 (pnh)의 치료를 위한 항-c5 항체의 피하 투여량 및 투여 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050169921A1 (en) * | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| EP3124029A1 (en) * | 2006-03-15 | 2017-02-01 | Alexion Pharmaceuticals, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement |
| SMT201700552T1 (it) * | 2013-03-14 | 2018-01-11 | Alnylam Pharmaceuticals Inc | COMPOSIZIONI DI iRNA DEL COMPONENTE DEL COMPLEMENTO C5 E LORO METODI DI USO |
| NZ711451A (en) * | 2014-03-07 | 2016-05-27 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
-
2016
- 2016-03-29 JP JP2017551276A patent/JP6944375B2/ja active Active
- 2016-03-29 WO PCT/US2016/024624 patent/WO2016160756A2/en not_active Ceased
- 2016-03-29 EP EP16715720.5A patent/EP3277715A2/en not_active Ceased
- 2016-03-29 US US15/560,606 patent/US20190135903A1/en not_active Abandoned